eosinophil recruitment

WHI-P97 is a rationally designed potent inhibitor of JAK-3. IC50 value: Target: JAK3 Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxygenase (5-LO) from the nucleoplasm to the nuclear membrane and consequently 5-LO-dependent leukotriene (LT) synthesis after IgE receptor/FcepsilonRI crosslinking by >90% at low micromolar concentrations. WHI-P97 did not directly inhibit the enzymatic activity of 5-LO, but prevented its translocation to the nuclear membrane without affecting the requisite calcium signal.

MEDI-2045 is a humanized monoclonal antibody targeting the interleukin-4 receptor alpha subunit (IL-4Ra/CD124). IL-4Ra is a pivotal receptor driving Type 2 inflammation, serving as an essential component of the shared receptor complexes for both IL-4 and IL-13. By specifically binding to IL-4Ra, this antibody dually blocks IL-4 and IL-13 signaling, thereby inhibiting the downstream JAK-STAT signaling pathway. This mechanism significantly attenuates inflammation involved in Th2 cell activation, B-cell class switching to IgE, and eosinophil recruitment, making it a critical tool for immunological research in asthma, atopic dermatitis, and other allergic diseases.